In bladder cancer cells, experimental downregulation of EP300 leads to doxorubicin and cisplatin resistance [14, 15] and, using a minimally transformed model of mammary epithelial cells in which EP300 has been downregulated, we have recently found an impaired caspase-9 and caspase 3/7 activation following paclitaxel treatment [17]. Here, EP300 is linked to urinary bladder cancer.